Actavis, Watson deal

Watson completed its acquisition of fellow generics company Actavis for €4.3 billion ($5.5 billion) in cash. Watson said it will change its name to Actavis and adopt a new trading symbol on the NYSE, effective next year (see BioCentury, July 16). ...